C
C10AA04 Fluvastatin
[C10AA] HMG CoA reductase inhibitors
[C10A] LIPID MODIFYING AGENTS, PLAIN
[C10] LIPID MODIFYING AGENTS
[C] Cardiovascular system
Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
---|---|---|---|---|---|---|---|---|
OPENING OF PERMEABILITY TRANSITION PORE (PTP) | 10 µM | 1 hour | Human | HepG2 | High-content screening assay | Decrease | MEC | 306 |
MEMBRANE POTENTIAL | 27.64±1.87 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
MEMBRANE POTENTIAL | human | HepG2 | MMP assay | Negative | IC50 | 163 | ||
MEMBRANE POTENTIAL | rat | hepatocytes | MMP assay | Negative | IC50 | 163 | ||
MEMBRANE POTENTIAL | >100 µM | 1 hour | Human | HepG2 | High-content screening assay | Negative | MEC | 306 |
ROS PRODUCTION | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | Increase | MEC | 306 |
Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
---|---|---|---|---|---|---|---|---|
Reactive oxygen species | 50 µM | 1 hour | Human | HepG2 | High-content screening assay | increase | MEC | 306 |
Pictogram | Signal | Statements | Precautionary Statement Codes |
---|---|---|---|
Danger |
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. H350 (100%): May cause cancer [Danger Carcinogenicity] |
P201, P202, P281, P308+P313, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) | |
Danger |
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation] H318 (100%): Causes serious eye damage [Danger Serious eye damage/eye irritation] H412 (100%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] |
P264, P270, P273, P280, P301+P312, P302+P352, P305+P351+P338, P310, P321, P330, P332+P313, P362, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) | |
(+)-(3R,5S)-fluvastatin | (-)-fluvastatin | (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid |
(3R,5S)-fluvastatin | (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid |
(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid | (3R,5S,E)-7-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid |
(E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid | (E,3R,5S)-7-[3-(4-fluorophenyl)-1-isopropyl-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid | (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid |
6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (3R,5S,6E)-rel- | 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (R*,S*-(E))-(+-)- | 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, (R*,S*-(E))-(+-)- |
6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)- | 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate | 93957-54-1 |
957F541 | ACT03305 | API0002749 |
BDBM86704 | BRD-K66296774-001-02-0 | C24H26FNO4 |
CAS-93957-54-1 | CAS_93957-54-1 | CCG-213323 |
CHEBI:38565 | CHEBI:93160 | CPD001453708 |
CS-1226 | Canef | Cranoc |
DL-108 | DSSTox_CID_636 | DSSTox_GSID_20636 |
DSSTox_RID_75707 | DTXSID2020636 | EN300-51915 |
FJLGEFLZQAZZCD-MCBHFWOFSA-N | Fluvastatin & Primycin | Fluvastatin [INN:BAN] |
Fluvastatin sodium L1483; | GTPL2951 | HMS2089P06 |
HMS3259J15 | HY-14664 | LS-7404 |
Lescol | NC00659 | NCGC00256490-01 |
NSC-758896 | NSC758896 | Pharmakon1600-01504911 |
Prestwick2_000859 | PubChem10727 | Q417942 |
SAM002548940 | SCHEMBL2846 | SCHEMBL556754 |
SR-05000001489-1 | Tox21_302765 | UNII-4L066368AS component FJLGEFLZQAZZCD-MCBHFWOFSA-N |
W-5176 | XU 62320 | XU-62320 |
ZINC1886617 | fluvastatin |